Despite Progress, More Work Needed To Harmonize FDA and EMA Criteria For Biowaivers
Executive Summary
While FDA took a big leap forward by waiving bioequivalence studies for BCS Class 3 drugs and aligning biowaiver rules with the EU, there is still work that needs to be done to harmonize solubility and permeability criteria. Until these differences are resolved, pharmaceutical manufacturers may still need to perform separate studies in getting biowaivers approved in these to jurisdictions. This issue is taking on more prominence now as ICH is looking into harmonizing biowaiver requirements worldwide.
You may also be interested in...
ICH Consults On Harmonized Criteria For Bioequivalence Study Waivers
The International Council for Harmonisation has issued draft guidance specifying the supportive data needed to classify a drug substance under the Biopharmaceutics Classification System and for biowaiver applications.
ICH Consults On Harmonized Criteria For Bioequivalence Study Waivers
The International Council for Harmonisation has issued draft guidance specifying the supportive data needed to classify a drug substance under the Biopharmaceutics Classification System and for biowaiver applications.
Manufacturing Regulatory Updates In Brief: Elemental Impurities, Class 3 Biowaivers, FDA Salt Policy
Manufacturing US regulatory updates for December 2017: Elemental impurities requirements begin Jan. 1, final guidance confirms BCS Class 3 biowaivers option, and FDA MAPP implements USP salt policy.